Advanced Filters
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
noise

Found 2,823 clinical trials

M Mika Kontro, MD,PhD

Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening

This is a multi center two-stage, two-arm, open label phase II study of venetoclax in combination with azacytidine in acute myeloid leukemia patients selected for therapy with ex vivo venetoclax sensitivity screening. This study will characterize the usability of ex vivo drug sensitivity testing for patient selection for selecting the …

18 years and older All Phase 2
C Chief Medical Officer, MD

At-Risk for Type 1 Diabetes Extension Study

This study is an extension of the NIH-sponsored AT-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who develop clinical type 1 diabetes after the conclusion of that trial, are eligible to enroll and receive teplizumab treatment within one year of diagnosis of …

100 years and younger All Phase 2
S Sarah Hamilton, MBiolSci

ADME Study of Acoziborole in Healthy Subjects

This is a single centre, open-label, single group, non-randomised, single oral dose study in healthy male subjects designed to assess the mass balance recovery, PK, metabolite profile and metabolite identification, and exploratory pharmacodynamics of acoziborole. It is planned to enrol 6 subjects. All subjects will receive an oral dose of …

18-55 years Male Phase 1
g guldeniz karadeniz cakmak

Sentinel Lymph Node Biopsy With Hybrid Technique in Breast Cancer

Sentinel lymph node (SLN) biopsy is the gold standard method to stage axilla in breast cancer. The aim of the study is to compare the efficiency of various methods to identify SLN is breast cancer patients.

18-90 years All Phase N/A
K Kelsey Fafara, BS

Precision Orthodontics: A Comparison of Custom vs Traditional Bracket Treatment Efficiency

This investigational testing aims to target multiple investigations sites to examine treatment efficiency metrics using a completely digital and patient-specific bracket treatment system for the correction of malocclusions.

10-65 years All Phase N/A
J Jack N Hutter, MD, MPH&TM, MAJ, MC, USA

A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy Adults

A Phase 1, open label clinical study to evaluate the safety, immunogenicity, tolerability and efficacy of Plasmodium falciparum Malaria Protein 013 (FMP013) combined with (ALF with QS-21), saponin molecule derived from the bark of Quillaja species (ALFQ)) in healthy adult volunteers at different doses and dosing schedules.

18-55 years All Phase 1
L Laila El Raee, B.D.S

Using the Roots of a Non Restorable Wisdom Tooth as a Block for Augmentation of Localized Defects

assess and compare the efficacy and safety of autogenous tooth roots for lateral alveolar ridge augmentation with staged implant placement in comparison to autogenous bone block.

100 years and younger All Phase 4
A Aurélien Marabelle, MD

Intratumoral Tilsotolimod a TLR-9 Agonist Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

Open label, phase Ib study of intratumoral tilsotolimod in combination with intratumoral ipilimumab and intravenous nivolumab. The trial will be divided into two parts: PART A: the first part will assess the safety of two regimen and will recruit patients with all types of injectable solid malignancies PART B: the …

18 years and older All Phase 1
T There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

A Study of LY3478045 in Healthy Participants

The main purpose of this study in healthy participants is to learn more about the safety of LY3478045 and any side effects that might be associated with it. The study will also measure how much LY3478045 gets into the bloodstream and how long it takes the body to get rid …

18-60 years All Phase 1
D Daiichi Sankyo Contact for Clinical Trial Information

Study of Single-dose DS-3201b in Participants With Hepatic Impairment

This is a Phase 1, open-label, parallel design, single-dose pharmacokinetic (PK) study to assess the safety, tolerability, and PK of a single dose of 50 mg of DS-3201b in participants with normal and impaired hepatic function.

18-75 years All Phase 1

Simplify language using AI